OCUL Share Price Performance
US$10.27
2.73 (36.21%)
42.9% undervalued intrinsic discount
US$18.00
Fair Value
Price US$10.27
AnalystLowTarget US$18.00
AnalystConsensusTarget US$24.17
AnalystHighTarget US$31.00
Fair ValueUS$18.00
Share Pricen/a
Ocular Therapeutix, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
OCUL Community Narratives
AN
Fair Value US$18 42.9% undervalued intrinsic discount
Regulatory Risks Will Hinder Ophthalmology Trials Yet Future Upside Emerges
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$24.17 57.5% undervalued intrinsic discount
OCUL: Pivotal Nonproliferative Diabetic Retinopathy Results Will Drive Future Share Upside
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$31 66.9% undervalued intrinsic discount
Aging Global Trends And Novel Delivery Will Expand Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Risks Will Hinder Ophthalmology Trials Yet Future Upside Emerges
Key Takeaways Heavy reliance on a single lead therapy exposes the company to regulatory and clinical risks that could threaten future revenue and earnings stability. Competitive pressures, payer cost controls, and potential generic entrants could limit pricing power, slow market expansion, and impact long-term margin growth.Read more
51
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$18
42.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
21.47%
Future PE
236.44x
Price in 2029
US$21.98
Aging Global Trends And Novel Delivery Will Expand Markets
Key Takeaways AXPAXLI's unique clinical advantages and potential label claims support premium pricing, durable market share, and strong long-term margin expansion insulated from price competition. Platform innovation and demographic-driven demand growth open multiple recurring revenue streams, reduce business risk, and increase chances of major partnerships or acquisition.Read more
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$31
66.9% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
20.92%
Future PE
91.93x
Price in 2029
US$37.79
OCUL: Pivotal Nonproliferative Diabetic Retinopathy Results Will Drive Future Share Upside
Key Takeaways Potential market leadership in ophthalmology driven by innovative product launches, data differentiation, and expansion into new high-burden eye disease indications. Accelerated commercialization, diversified revenue streams, and strong financial position provide room for growth and protect against immediate dilution risks.Read more
367
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$24.17
57.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
20.87%
Future PE
164.64x
Price in 2029
US$29.46
Trending Discussion
Recently Updated Narratives
AN
OCUL: Higher Sanofi Bid And SOL-1 Data Will Drive Bullish Repricing
Fair Value: US$18 42.9% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OCUL: Potential Sanofi Bid And Late Stage Trials Will Reshape Outlook
Fair Value: US$31 66.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
OCUL: Phase 3 Retinal Program Progress Will Drive Future Upside Potential
Fair Value: US$24.17 57.5% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ocular Therapeutix, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.22
- -292.04%
- -511.90%
- 10.9%
About OCUL
- Founded
- 2006
- Employees
- 325
- CEO
- WebsiteView website
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
